714 related articles for article (PubMed ID: 29330305)
1. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
2. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
3. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.
Patel KR; Nott JD; Barb AW
Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031
[TBL] [Abstract][Full Text] [Related]
4. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
[TBL] [Abstract][Full Text] [Related]
5. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
Roberts JT; Barb AW
J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
[TBL] [Abstract][Full Text] [Related]
6. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.
Roberts JT; Patel KR; Barb AW
Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963
[TBL] [Abstract][Full Text] [Related]
7. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
Falconer DJ; Subedi GP; Marcella AM; Barb AW
ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
[TBL] [Abstract][Full Text] [Related]
8. Antibody receptors steal the sweet spotlight.
Oliva KD; Cavanaugh JM; Cobb BA
J Biol Chem; 2018 Mar; 293(10):3490-3491. PubMed ID: 29523693
[TBL] [Abstract][Full Text] [Related]
9. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.
Patel KR; Roberts JT; Barb AW
Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
[TBL] [Abstract][Full Text] [Related]
11. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
Lee HS; Im W
Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
[TBL] [Abstract][Full Text] [Related]
12. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
Kremer PG; Barb AW
J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896
[TBL] [Abstract][Full Text] [Related]
13. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
[TBL] [Abstract][Full Text] [Related]
14. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
15. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.
Subedi GP; Barb AW
MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264
[TBL] [Abstract][Full Text] [Related]
16. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
17. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy.
Subedi GP; Falconer DJ; Barb AW
Biochemistry; 2017 Jun; 56(25):3174-3177. PubMed ID: 28613884
[TBL] [Abstract][Full Text] [Related]
19. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
20. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.
Hayes JM; Frostell A; Karlsson R; Müller S; Martín SM; Pauers M; Reuss F; Cosgrave EF; Anneren C; Davey GP; Rudd PM
Mol Cell Proteomics; 2017 Oct; 16(10):1770-1788. PubMed ID: 28576848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
